Analysts Set Envista Holdings Corporation (NASDAQ:NVST) Price Target at $26.00

Envista Holdings Corporation (NASDAQ:NVST) has received an average rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $26.00.

NVST has been the subject of several recent research reports. Zacks Investment Research raised Envista from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Robert W. Baird lowered their price target on Envista from $25.00 to $23.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Bank of America reaffirmed a “neutral” rating and issued a $18.00 price target (down previously from $19.50) on shares of Envista in a research report on Wednesday, May 13th. JPMorgan Chase & Co. lowered their price target on Envista from $32.00 to $27.00 and set an “overweight” rating for the company in a research report on Tuesday, March 17th. Finally, Morgan Stanley lowered their price target on Envista from $20.00 to $18.00 and set an “equal weight” rating for the company in a research report on Thursday, May 14th.

Envista stock traded up $0.20 on Tuesday, hitting $21.14. 1,843,680 shares of the stock traded hands, compared to its average volume of 3,447,063. The business’s fifty day simple moving average is $17.78 and its 200 day simple moving average is $24.13. Envista has a 1 year low of $10.08 and a 1 year high of $33.30.

Envista (NASDAQ:NVST) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). The business had revenue of $547.20 million during the quarter, compared to analyst estimates of $569.07 million. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis.

Large investors have recently modified their holdings of the business. Bamco Inc. NY purchased a new position in Envista in the 4th quarter worth about $110,000. US Bancorp DE bought a new stake in shares of Envista during the 4th quarter valued at about $159,000. Boston Common Asset Management LLC bought a new stake in shares of Envista during the 4th quarter valued at about $1,394,000. California Public Employees Retirement System bought a new stake in shares of Envista during the 4th quarter valued at about $5,148,000. Finally, Hall Laurie J Trustee bought a new stake in shares of Envista during the 4th quarter valued at about $177,000.

About Envista

Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.

Further Reading: How To Calculate Debt-to-Equity Ratio

Analyst Recommendations for Envista (NASDAQ:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.